Lupin Launches Atorvastatin Calcium Tablets USP

Pharma major Lupin Limited (Lupin) announced the launch of Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product will be manufactured at Lupin's Nagpur facility in India.

Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg, is the generic equivalent of Lipitor® Tablets, 10 mg, 20 mg, 40 mg and 80 mg, of Pfizer Inc., and indicated to lower cholesterol in blood for adults and children over 10 years of age. Atorvastatin is also prescribed to lower the risk of heart attack and stroke in patients with cardiovascular diseases, diabetes and other risk factors such as eye problems, kidney diseases or high blood pressure.

Atorvastatin Calcium Tablets USP (RLD: Lipitor®) had annual sales of approximately USD 559 million in the U.S. (IQVIA MAT July 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.997.8 as compared to the previous close of Rs. 979.55. The total number of shares traded during the day was 94280 in over 3586 trades.

The stock hit an intraday high of Rs. 1022.35 and intraday low of 978.75. The net turnover during the day was Rs. 94476212.

Source : Equity Bulls

Keywords